Citation
Raida, Ludek, et al. "Comparison of New Flu-bu12-tg Conditioning With the Standard Bu-cy Myeloablative Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia." Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, vol. 155, no. 4, 2011, pp. 327-32.
Raida L, Tucek P, Faber E, et al. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155(4):327-32.
Raida, L., Tucek, P., Faber, E., Vondrakova, J., Rusinakova, Z., Skoumalova, I., Hubacek, J., Jarosova, M., Katrincsakova, B., Pikalova, Z., Kurfurst, P., & Indrak, K. (2011). Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 155(4), 327-32. https://doi.org/10.5507/bp.2011.040
Raida L, et al. Comparison of New Flu-bu12-tg Conditioning With the Standard Bu-cy Myeloablative Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155(4):327-32. PubMed PMID: 22336644.
TY - JOUR
T1 - Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
AU - Raida,Ludek,
AU - Tucek,Pavel,
AU - Faber,Edgar,
AU - Vondrakova,Jana,
AU - Rusinakova,Zuzana,
AU - Skoumalova,Iva,
AU - Hubacek,Jaromir,
AU - Jarosova,Marie,
AU - Katrincsakova,Beata,
AU - Pikalova,Zuzana,
AU - Kurfurst,Pavel,
AU - Indrak,Karel,
PY - 2012/2/17/entrez
PY - 2012/2/18/pubmed
PY - 2012/6/12/medline
SP - 327
EP - 32
JF - Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
JO - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
VL - 155
IS - 4
N2 - AIMS: This study compares the outcomes of patients with high-risk acute myeloid leukemia (AML) who underwent allogeneic stem cell transplantation (SCT) after conditioning combining busulfan (16 mg/kg orally) and cyclophosphamide (120 mg/kg intravenously) (BU-CY) with those allografted after administration of fludarabine (150 mg/m(2) intravenously), busulfan (12 mg/kg orally) and thymoglobulin (6 mg/kg intravenously) (FLU-BU12-TG). MATERIAL AND METHODS: SCT after BU-CY and FLU-BU12-TG was performed in 21 and 10 AML patients. There were no significant differences between groups in number of patients treated in complete disease remission, gender, age, donors, CD34+, mononuclear cell (MNC) count in the graft and follow-up period. However, significantly more SCTs from unrelated (90% vs. 19%; p=0.00018) and HLA-mismatched donors (50% vs. 0%; p=0.0004) were performed in the FLU-BU12-TG group. The Cox proportional hazards model was used to assess the risk of post-transplant AML relapse and non-relapse mortality (NRM). The probability of post-transplant 2-year event-free survival (EFS) and overall survival (OS) were calculated using the Kaplan-Meier method. RESULTS: No significant differences were found between the FLU-BU12-TG and BU-CY groups in risk of AML relapse (HR=1.036; 95% CI [0.102 - 10.47]; p=0.9), post-transplant NRM (HR=0.25; 95% CI [0.031 - 1.96]; p=0.18), 2-year EFS (89% vs. 43%; p=0.19) or OS (79% vs. 57%; p=0.23). CONCLUSION: These pilot results demonstrate the efficacy of the new FLU-BU12-TG conditioning regimen in patients allografted for high-risk AML. This conditioning might become an alternative approach in patients at high risk of severe post-transplant complications after the standard BU-CY myeloablative regimen.
SN - 1213-8118
UR - https://www.unboundmedicine.com/medline/citation/22336644/Comparison_of_new_flu_bu12_tg_conditioning_with_the_standard_bu_cy_myeloablative_regimen_in_patients_undergoing_allogeneic_stem_cell_transplantation_for_acute_myeloid_leukemia_
L2 - http://mefanet.upol.cz/BP/2011/4/327.pdf
DB - PRIME
DP - Unbound Medicine
ER -